Plasma phosphorylated tau181 and neurofilament light chain linked to neurodegeneration in dementia

Takeaway

  • Baseline levels and longitudinal changes in plasma phosphorylated-tau181 levels are associated with future neurodegeneration and cognitive decline in Alzheimer’s disease.

Why this matters

    The ability to monitor disease progression in Alzheimer’s disease is important to enable individualized treatment. These novel findings suggest that plasma phosphorylated tau at threonine 181 is an accessible, minimally invasive biomarker of neurodegeneration and cognitive decline which, unlike plasma neurofilament light chain, is specific for Alzheimer’s disease.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.